A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Albert Gris‐Oliver et al.|EMBO Molecular Medicine|2018Cited by 271
Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationBenedetta Pellegrino, Violeta Serra|Cancer Research|2022Cited by 94
286P Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry studyAntonino Musolino, Fabio Falcini, Ò. Serra et al.|Annals of Oncology|2023Cited by 1